Kite Pharma (Gilead Sciences)
Santa Monica, CA
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Kite Pharma (Gilead Sciences)
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Santa Monica, CA
- Modalities
- CAR-T (autologous), CAR-T (in vivo), CD19-targeted, BCMA-targeted, CD19/CD20 dual-targeting
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Kite Pharma (Gilead Sciences)
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T (autologous), CAR-T (in vivo), CD19-targeted, BCMA-targeted, CD19/CD20 dual-targeting
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (5 modalities)
Recent News 10 articles
Biotech faces a reckoning: 'We've lost our luster in cell therapies' - Fierce Biotech
With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms - Fierce Pharma
‘We have to go for it’: CAR-T’s success in glioblastoma prompts call for research investment - Healio
Who Are the Global Leaders in CAR T-Cell Therapy? Top 10 Companies List - Global Growth Insights
Cell therapy reckoning: Pivot to autoimmune leaves unmet need in oncology - Fierce Biotech
Gilead's Kite ties itself to Refuge's gene expression platform in blood cancer CAR-T deal - Fierce Biotech
Gilead's Kite taps longtime Amgen alum as new global commercial head - Fierce Pharma
ASCO: Kite's CAR-T passes lymphoma safety trial with flying colors - Fierce Biotech
How to get cell therapies flying off-the-shelf - Fierce Biotech
CAR T-cell therapy shows ‘high and durable response rates’ in adults with B-cell ALL - Healio
Represent this organization? Contact us to verify or update this profile.